Kjersem, Janne B <br/><br/>
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.  [electronic resource] 

 -  BMC cancer  May 2014 
 - 340 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-14-340  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cetuximab<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Kaplan-Meier Estimate<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Mutation<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Polymorphism, Single Nucleotide<br/>Proportional Hazards Models<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Receptors, IgG--genetics<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult<br/>ras Proteins--genetics